Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy
2期
已完成
NCT05605301
| 适应症 | Epilepsy; Seizure |
|---|
| 分期 | 2期 |
|---|
| 申办方 | University of Virginia |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 9 人 |
|---|
| 干预(药物) | Oral 2-Deoxy-D-Glucose (2DG) |
|---|
| 开始日期 | 2022年9月2日 |
|---|
| 完成日期 | 2024年2月5日 |
|---|
| 结果公布日 | 2026年6月9日 |
|---|
摘要
This project studies how 2-deoxy-glucose (2DG) pills are absorbed and distributed in people with epilepsy. 2DG is similar to glucose, the main energy source for the brain, but it cannot be used as energy. During seizures, neurons are at a very high metabolic state with huge glucose metabolism as glycolysis is accelerated to supply the high metabolic needs of a seizure. 2DG is taken up by cells but cannot be metabolized by the first enzyme in the glycolytic pathway, thus is stops, or "clogs up", glycolysis. Since brain metabolism is almost entirely dependent on glucose as an energy source, glycolysis is arrested and may stop seizures. It is hoped that 2DG will stop seizures by interfering with the brain's energy use. This is an open-label phase 2 study of the pharmacokinetics (PK), safety, and tolerability of 2DG administered orally to adult epilepsy patients. A 3-level 2DG dose escalation is planned in sequential cohorts of 3 subjects in each cohort with review of each cohort before proceeding to the next cohort. On the day of oral 2DG exposure, subjects will receive a single dose of 40 mg in the first cohort, a single dose of 60 mg in the second cohort, and two 60 mg doses (60 mg
Area Under the Curve From Time Zero to Last Observed Time Point (AUClast)
From time of drug administration until 24 hours post-dose · hour*ug/mL
| 2DG 40 mg Single Dose | 2.81 ± 0.49 hour*ug/mL |
|---|
| 2DG 60 mg Single Dose | 2.93 ± 1.13 hour*ug/mL |
|---|
| 2DG 60 mg Twice Daily | 4.16 ± 0.57 hour*ug/mL |
|---|
Area Under the Curve From Time Zero Extrapolated to Infinity (AUCinf)
From time of drug administration until 24 hours post-dose · hr*ug/mL
| 2DG 40 mg Single Dose | 3.56 ± NA hr*ug/mL |
|---|
| 2DG 60 mg Single Dose | 3.19 ± 1.59 hr*ug/mL |
|---|
| 2DG 60 mg Twice Daily | 4.71 ± 0.81 hr*ug/mL |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。